Clinical trials: Relapsed Hematologic Malignancy
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT05334823
- Testing
- pCAR-19B cells
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Leukemia, Chronic Myeloproliferative Disease
A Phase I Trial of ZIO-101 in Hematologic Cancers
This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical.
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma
- Trial name
- NCT00592046
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Relapsed or Refractory Multiple Myeloma
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells [white…
- Trial name
- NCT05757973
- Testing
- Talquetamab
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma (MM)
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
- Trial name
- NCT04649073
- Testing
- OPC-415
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Multiple Myeloma
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or…
- Trial name
- NCT07312188
- Testing
- F182112+P, F182112+CD38
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Multiple Myeloma
Combination Study for High Risk Multiple Myeloma Patients
Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM remains with poor prognosis and a therapeutic challenge.
- Trial name
- NCT03104270
- Testing
- Elotuzumab, Pomalidomide, Carfilzomib
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label, dose-escalation/expansion phase 1/2a study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for…
- Trial name
- NCT06223646
- Testing
- KQ-2003 CAR T-cells
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Multiple Myeloma
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
This is a phase I/II multicenter, open label, nonrandomized study for patients with Multiple Myeloma (MM) who will receive treatment with carfilzomib in place of bortezomib using the same bortezomib-containing combination regimen…
- Trial name
- NCT01365559
- Testing
- Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
- Where
- 9 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Chronic Lymphocytic Leukemia
SPC2996 in Chronic Lymphocytic Leukaemia
The purpose of this study is to determine whether SPC2996 is effective and safe in the treatment of Chronic Lymphocytic Leukaemia (CLL)
- Trial name
- NCT00285103
- Testing
- SPC2996
- Where
- 12 sites in United States, Denmark and 2 more
- Volunteers
- 46 people
- Sponsor
- Santaris Pharma A/S
Acute Lymphoblastic Leukemia
Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
Outcomes for children with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) are dismal. Therefore, the investigators performed this multicenter, phase II study to evaluate the efficacy and , safety and pharmacokinetic…
- Trial name
- NCT02544789
- Testing
- Clofarabine
- Where
- 6 sites in China
- Volunteers
- 44 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Leukemia
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and…
- Trial name
- NCT05886491
- Testing
- GDX012, Chemotherapy Agents
- Where
- 11 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Takeda
Multiple Myeloma
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
- Trial name
- NCT00609817
- Testing
- GCS-100, Bortezomib/Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- La Jolla Pharmaceutical Company
Refractory or Relapsed Multiple Myeloma
LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).
- Trial name
- LEGEND-2 (NCT03090659)
- Testing
- LCAR-B38M CAR-T cell injection
- Volunteers
- 100 people
- Sponsor
- Nanjing Legend Biotech Co.
Multiple Myeloma
CT Antigen TCR-Engineered T Cells for Myeloma
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
- Trial name
- NCT01892293
- Testing
- Treatment with NY-ESO-1c259-modified T cells
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Adaptimmune
Relapsed or Refractory Hematologic Malignancies, Leukemia
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between…
- Conditions
- Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma, Multiple Myeloma (MM)
- Trial name
- NCT07107204
- Testing
- BT02
- Volunteers
- 116 people
- Sponsor
- Biotroy Therapeutics
Multiple Myeloma
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of NOX A12 alone and in combination with a background therapy of bortezomib and dexamethasone (VD) chemotherapy in previously treated patients with multiple myeloma…
- Trial name
- NCT01521533
- Testing
- NOX-A12
- Where
- 10 sites in Austria, France and 2 more
- Volunteers
- 28 people
- Sponsor
- TME Pharma AG
Multiple Myeloma
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory…
- Trial name
- NCT00833833
- Testing
- Pomalidomide, Dexamethasone, Aspirin
- Where
- 19 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Celgene Corporation
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT05878184
- Testing
- SC291
- Where
- 10 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Sana Biotechnology
Multiple Myeloma, Renal Impairment
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and…
- Trial name
- POM Renal (NCT01575925)
- Testing
- 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Celgene
Multiple Myeloma, Plasma Cell Disorder
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
- Trial name
- NCT04879043
- Testing
- HDP-101
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 78 people
- Sponsor
- Heidelberg Pharma AG